At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Cognitexdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Open-label Study to Assess the Efficacy of Cognitex in Elderly Subjects With Memory Impairment
In Brief
A Phase 4 clinical trial evaluating Cognitex for Elderly and Memory Impairment. Completed, enrolled 30 participants across 1 site.
Detailed Summary
A Single-Center, Open Label Study to Assess the Efficacy of Cognitex in Elderly Subjects with Memory Impairment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsElderly, Memory Impairment
CountriesIsrael
CollaboratorsEnzymotec
Timeline
Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartAug 2008
Primary CompletionMar 2009
Study CompletionAug 2009
TodayJul 2026
First PostedJul 22, 2008
Enrollment StartAug 1, 2008
Primary CompletionMar 1, 2009
Study CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.9 years ago
Interventions
Cognitexdietary
Treatment will consist of one capsule of Cognitex (Life Extension, USA), three times a day, with meals, delivering a total of 600 mg GPC, 100 mg PS-omega 3, 20 mg vinpocetine, 50 mg uridine-5'-monophosphate (disodium), 550 mg plant extracts (150 mg wild blueberry, 125 mg ashwagandha, 150 mg grape seed, 125 mg hops, ginger and rosemary). Duration: 15 weeks